122
Participants
Start Date
September 21, 2009
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
Crizotinib
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Questionnaire Administration
Ancillary studies
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Institutes of Health Clinical Center, Bethesda
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
University of Alabama at Birmingham Cancer Center, Birmingham
Vanderbilt University/Ingram Cancer Center, Nashville
St. Jude Children's Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital of Orange County, Orange
UCSF Medical Center-Parnassus, San Francisco
UCSF Medical Center-Mission Bay, San Francisco
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Hospital for Sick Children, Toronto
Collaborators (1)
National Cancer Institute (NCI)
NIH
Pfizer
INDUSTRY
Children's Oncology Group
NETWORK